CD8A and acute myeloid leukemia: In this study, we aimed to evaluate the baseline BM CD8+/CD3+ CTL subset in newly diagnosed AML patients and investigate its relationship with standard prognostic factors, response to induction therapy, and disease outcomes using multiparameter flow cytometry on fresh BM samples collected at diagnosis.